The patent covers a guidewire with enhanced optical sensing capabilities, allowing it to sense locations, thickness, and structure of the arterial walls as it navigates through the body. The concept and technology, which are complimentary to Kensey Nash’s Safe-Cross radio frequency (RF) chronic total occlusion (CTO) system, will allow the company to develop next generation CTO devices with enhanced guidance and revascularization capabilities.
The Safe-Cross system uses a forward-looking guidance system and RF energy to safely cross and re-canalize chronic total occlusions in the coronary and peripheral arteries.
Joseph Kaufmann, president and CEO of Kensey Nash, said: “We are very pleased to add this patent to our CTO intellectual property portfolio. By building upon the foundation of our current technology, we expect to broaden the Safe-Cross System’s capabilities as we develop additional tools to further improve clinical outcomes in both coronary and peripheral CTO procedures.”